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There is suggestive evidence that certain diseases of man, e.g. disseminated 
encephalomyelitis and thyroiditis, may result from immune responses directed 
against  his  own  (autologous)  tissues.  This  "autoallergic"  concept  of disease 
derives most support from several interrelated,  well established  observations 
in experimental animals. 
Certain  tissues,  e.g. brain,  thyroid,  and testis, have long been known to possess 
antigenic  activity and,  when  injected  into  experimental animals,  elicit  circulating 
antibodies which  react specifically with the corresponding tissue in vitro (1-7). It is 
also known that animals injected with these tissues  emulsified in Freund's adjuvant 
may develop striking tissue damage restricted to the organ in question; v/z., allergic 
encephalomyelitis, thyroiditis, and aspermatogenesis, respectively (reviewed by Pater- 
son, reference  8). Each of these diseases may be induced by injection of an animal's 
own  (autologous)  tissues  (9-11).  The  antibodies produced  by a  sensitized  animal 
react specifically in vitro with his own brain, thyroid, or testes (10-12). 
In  a  recent  review  (8)  of allergic  encephalomyelitis  (AE)  and  other  analogous 
experimental "autoallergic" diseases,  it was stressed that the existing data did not 
yet justify the  selection  of one type of immune response over another as  the  re- 
sponsible  mechanism for these diseases.  Events during the past 4 years have not re- 
quired modification  of this view. There is ample experimental evidence that the com- 
plement-fixing  (CF)  antibrain  antibodies,  called  forth  by brain  sensitization,  and 
directed against ethanol-soluble  brain antigens do not cause AE (8).  The strongest 
support for this conclusion  is the observation that the CF antibrain antibodies may 
be elicited  by non-mammalian (frog, turtle, and snake) nervous tissue which lack the 
capacity to induce AE (13). The unsuccessful  attempts by several workers to transfer 
AE passively with antibrain immune serum (reviewed  by Chase,  reference  14) have 
been cited often as convincing  evidence that circulating antibody plays  no role in 
AE (see reviews by Waksman, references  15-17).  As discussed  elsewhere  (18), other 
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interpretations are possible.  For example, passively administered  antibrain  antibody 
may not cross the  blood-brain barrier  in sufficient amounts  to cause AE in intact 
normal animals. It is also possible  that the unsuccessful attempts to transfer AE using 
immune  serum  reflect current lack  of information  about key factors necessary for 
such transfer. 
In the last few years, much has been written  about the importance of ddayed- 
type hypersensitivity to brain in the pathogenesis of AE (see reviews by Waksman, 
references 15-17). According to this view, AE is believed to result from an interaction 
between  nervous  tissue  antigen  and  "sensitized  ceils"  immunologicaliy committed 
to brain and spinal cord antigen(s)  but not producing conventional serum antibody. 
The evidence for this view is indirect and not always consistent. For example, rabbits 
with  AE  or  destined  to  develop  AE may exhibit  cutaneous reactivity  resembling 
delayed-type reactions to brain extracts (19).  Such reactions, however, also occur in 
other rabbits which do not develop the disease  (19).  In the rat, which regularly de- 
velops AE, convincing cutaneous reactivity of this type has not been demonstrated 
in spite of serious attempts to do so in our laboratory (20). It should be stressed that 
no direct evidence exists that delayed-type hypersensitivity either does or does not 
play an important role in this disease.  The transfers of AE in rats (21, 22) by means 
of living lymph node ceils derived from spinal cord-sensitized donors did not clarify 
this issue.  While these studies  did provide direct evidence that the disease  has an 
immune mechanism and that lymph node cells produce the immune factor, they have 
not defined its nature. For as stated previously (18, 21, 22) and worthy of reemphasis 
here,  it is impossible  to determine  whether  the lesions  of AE in recipient animals 
result from minute quantities of conventional serum antibody produced and released 
by the donor lymph node ceils  after  their  transfer.  Or,  alternatively,  whether  the 
lesions  are due to a direct interaction between antigen in the brain of recipients and 
donor lymph node cells engaged in a delayed-type hypersensitivity response. 
There have been clues which suggest a protective role for the CF antibrain  anti- 
bodies in AE. In 1950, Thomas, Paterson, and Smithwick (23) noted that AE occurred 
more often  and  was  more  severe  in  dogs without  CF  antibrain  antibody.  It was 
suggested then that "... the antibody might represent a protective reaction." Sub- 
sequently it was found that rabbits  sensitized  to brain  or spinal  cord in adjuvant 
v/a the subcutaneous route almost invariably produced high titer  CF antibody but 
rarely developed AE (13). In contrast, guinea pigs sensitized by any route, developed 
rapidly fatal AE and  CF antibody could rarely be detected  (24).  More recent ob- 
servations revealed that rats although severely paralyzed 2 or 3 weeks after sensitiza- 
tion, almost always recovered and appeared clinically wall 6 to 9 weeks after sensiti- 
zation (see below and reference 25).  CF antibrain antibody was observed commonly 
in rats during recovery from the disease.  Finally, rats which had recovered at 6 weeks, 
at  a  time when  CF antibody was present,  upon reinjection  of nervous tissue plus 
adjuvant usually failed to exhibit again any clinical  signs of AE or have pathological 
evidence  of  the  disease  (25).  The  preliminary  finding  of  Florey,  summarized  by 
Vulp6 (26), that guinea pig antibraln  serum may interfere with active induction of 
AE in this species  of animals, further supported the concept that CF antibrain anti- 
body might have a  protective function. For the above reasons, it seemed probable 
that  passively  administered  immune  rat  serum  containing  CF antibrain  antibody 
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The  purpose  of  this  paper  is  to  present  data  which  show  that  AE  is  sup- 
pressed  in  rats  sensitized  to  nervous  tissue  and  treated  with  rat  antibrain 
serum.  Evidence  is  presented  consistent  with  the  view  that  the  suppressive 
or protective  effect of antibrain  serum  is  due  to  CF  antibrain  antibody. 
Materials and Methods 
General Plan.--The protocol of the experiments designed to evaluate the role of antibrain 
serum in suppression of AE is presented in schematic form in Fig. 1. A large number of pro- 
FIo.  1.  Design of experiments for evaluating effect of antibrain  serum  on  induction of 
AE. 
spective serum donor rats (60 to 70 animals in most of the experiments) were sensitized with 
guinea pig spinal cord emulsified in adjuvant.  1 to 6 weeks  later,  the donor rats were bled, 
their sera collected and pooled. Then, prospective serum recipients were sensitized to spinal 
cord plus  adjuvant  in  the  same manner  as  the  serum  donors.  In most  experiments,  each 
recipient was injected intravenously with a pool of serum 4 to 5 hours prior to sensitization. 
Thereafter, injections of the serum were given on alternate days through the 18th day after 
sensitization, daring which time the rats were examined daily for clinieal signs of AE. On the 
19th day, the actively sensitized and serum-treated rats were sacrificed  and their brains and 
spinal cords examined for microscopic lesions of AE. 
Animals.--Albino  Wistar  rats,  1 of either  sex,  weighing  125  to  300  gm  were  employed. 
Hartiey guinea pigs, 2 of either sex, weighing 500 to 800 gm were used as a source of spinal cord 
1 Wistar rats purchased from Hemlock Hollow Farms,  Wayne, New Jersey or  Carworth 
Farms, New City, New York. 
2 Hartiey guinea pigs obtained from Hemlock Hollow Farms or Miss Lucy V.  Via, Free 
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antigen. Animals were housed in wire cages and fed a standard diet of commercial food pellets 
(supplemented with "greens" in the case of guinea pigs) and tap water ad l/b. 
Tissue-Adjuvant  Inocula  and Sensiti~tlion  of Animals.--Guinea  pig spinal cord  was  re- 
moved and stripped of meninges aseptically and stored at --17°C for 1 to 7 days before used. 
The guinea pig kidneys had been aseptically removed and stored at --17 to -24°C for 1 year 
prior to use.  Thawed portions of  tissues were homogenized in a  Ten Broeck grinder with 
0.25 per cent phenol in distilled water to give a  33 per cent tissue (wet weight) homogenate 
and emulsified in complete adjuvant as previously described  (13,  21, 24).  Each rat was in- 
jected intracutaneousiy with 0.1 ml of tissue-adjuvant inoculum in each of 6 sites over the 
back and 0.1 ml in the ventral neck. 
The  Serum  Pools and  Their  Use.--Serum-donor  rats  were  bled  aseptically  by  cardiac 
puncture under ether anesthesia. The blood was allowed to  clot in sterile siliconized glass 
tubes  3 for 1 to 2 hours at room temperature followed by 4 to 8 hours at 4°C. The sera were 
collected  by  centrifugation at  4°C  and  pooled.  In  several experiments,  serum pools were 
deliberately prepared to include only serum of rats which had exhibited clinical signs of AE 
before bleeding. Other pools were prepared from sera of rats which had remained clinically 
well.  These serum pools were designated by the letters "A"  (prior clinical signs of AE)  or 
"B" (no prior signs), respectively. Once so designated, an "A" or "B" serum pool was used 
for all serum treatment of a  given group of sensitized recipients. All serum pools were stored 
at 4°C in sterile rubber-stoppered glass vials. From 3 to 14 days elapsed between preparation 
of the pool and initial injection of recipients. The serum pool from rats sensitized to guinea 
pig kidney was prepared by pooling individual rat sera which had been stored at  -17  to 
-25°C for 14 months. One serum pool, derived from rats sensitized to guinea pig spinal cord 
plus adjuvant 1 to 6 weeks prior to bleeding, was treated with 2-mereaptoethanol in a  final 
concentration of 0.1 ~  as previously described (27), a  procedure known to destroy CF anti- 
brain antibody. Two serum pools, checked for bacterial contamination at the time they were 
prepared and after their use some 4  weeks later gave no bacterial growth on sheep blood. 
Rats were usually kept in an incubator at 37°C for 2 to  10 minutes prior to intravenous 
injection of serum to induce peripheral venous dilatation and facilitate injection. Each animal 
was etherized lightly and gently hand-held by an assistant during injection of serum into 
either a  leg vein  (exposed by prior application of  a  depilatory)  or lateral vein of  the tail. 
Injection of volumes of 1.0 to 2.0 ml of serum required only 2 to 3 minutes and gave no un- 
toward clinical signs. 
Assay of Rat Serum for Complement-Fixing (CF)  Antibrain  Antibodies.--A  50 per cent 
hemolytic end-point technique was employed.  4 This technique as well as the details concerning 
preparation of ethanol extracts of rat brain for use as antigens has been described in previous 
reports from this laboratory (21,  24). If more than six 50 per cent hemolytic units of com- 
plement (C'H~),  of exactly 100 C'Hs0 available, were fixed specifically by serum in presence 
of brain antigen, that serum was considered to contain antibrain antibody. Justification for 
this interpretation, based  on  prior  experience  with appropriate  control  studies,  has been 
described in detail (21, 24). 
Histological Studles.--Brains and spinal cords were fixed in 10 per cent formaldehyde and 
then cut into blocks, paraffin-embedded, cut at 5 to 10 microns, and stained with hematoxy- 
lin-eosin. A minimum of 7, in most cases 14, different sections of brain-spinal cord  of  each 
animal were examined microscopically for lesions of AE. The brain sections included trans- 
8 Siliconizing done with desicote,  Beckman Instruments,  Inc.,  Fullerton, California.  All 
glassware in this study was processed through sulfuric acid-dichromate and repeatedly rinsed 
in tap water and then distilled water before being sterilized for use. 
4 Complement,  sheep  red  cells,  and  anti-sheep  cell  hemolysin obtained  from  Certified 
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verse cuts through (a) the cerebrum at level of the thalamus, (b) the mesencephalon including 
the 3rd ventricle, and  (c) the cerebellum-pons in the region of the 4th ventricle. The spinal 
cord sections included at least 3 longitudinal cuts through the cervico-thoracic segments and 
1 cut through the lumbar region. 
Criteria for Clinical Aspects of AE and Grading of Histological Lesions of AE.--I~ts were 
observed daily and checked for neurological signs noting, in particular, the gait, strength of 
hindlegs, and righting reflexes. Any animal exhibiting gross ataxia on 2 or more consecutive 
days and/or paralysis of one or both hindlegs for 1 or more days was recorded as showing 
clinical signs of AE. 
The 7  (or more)  stained  sections of brain and spinal cord from each rat were examined 
microscopically by each author for lesions  of AE. It was usually easy to determine whether 
an animal did or did not have characteristic lesions,  positive or negative, (24).  Since it soon 
was apparent that minimal disease (as judged by relatively few lesions) had occurred in many 
of the rats treated with serum, the following arbitrary and reproducible grading system was 
used. Even if only 1 discrete focal area of definite vasculitis was found, the animal was con- 
sidered positive. If up to 6 discrete, focal areas of vascular-perivascular inflammation char- 
acteristic of AE were found in the 7 to  14 sections examined, the animal was classified  as 
having "few lesions." If more than 6 areas were demonstrable,  the animal was classified  as 
having "many lesions." In most instances, those animals classified as having "many lesions" 
had disseminated, intense lesions within the brain and/or spinal cord. 
EXPEI~  17~RNTAL 
Time-Course  of AE in  Rats.--For purposes  d  reference,  experience  with 
induction of AE in albino  rats during the past 3 years is set out in Table I. 
The data provide a basis  for predicting the occurrence  of AE in rats in our 
laboratory at different times after sensitization.  The observations  have direct 
bearing on the serum-suppression  data to be presented below. As can be seen 
(Table I), rats given a single injection of guinea pig spinal cord plus adjuvant 
remain clinically well through the 8th day after sensitization.  Demonstrable 
histological evidence of AE can be found by the 7th or 8th day in a few rats. 
Clinical signs and lesions of AE reach peak incidence between the 15th to 18th 
day after sensitization.  At this time, approximately half of the sensitized ani- 
mals exhibit clinical signs  of AE. Virtually all sensitized  rats have demon- 
strable lesions of AE. During the 3rd week after sensitization  rats uniformly 
begin to improve clinically with gradual waning of neurological signs. Lesions 
of AE are  now less frequent. It is of considerable  interest that by the 29th 
to 39th day after sensitization full clinical recovery has usually ensued;  and 
only an occasional animal exhibits persistence  of clinical signs. An invariable 
accompaniment of this clinical recovery  is the marked decrease in proportion 
of rats with lesions of AE during this time. Around the 42nd to 44th day an 
occasional rat exhibits  recurrence  of clinical signs or may, for the first time, 
exhibit neurological signs.  This apparent resurgence  of clinical signs at this 
time is accompanied  by an increase  in proportion of rats with lesions of AE. 
By the 63rd day after sensitization rats are clinicaUy well and lesions have 
virtually disappeared.  Thus,  in  the  rat  sensitized  in  this fashion,  AE  is  a 760  SUPPRESSION  OF  ALLERGIC  ENCEPIKALOM'YELITIS 
TABLE I 
Time-Course  of Allergic  Encephalomyditis  (AE) in 433 Control Rats Sensitized  to a 
Standard Nervous  Tissue and Adjuvant Emulsion during  the Period  1959 to 1962 
Time between 
sensitization 
and sacrifice 
days 
6 
No. of 
experiments 
No. Of rats 
sensitized* 
18 
Cllnical-pathological  status 
of rats on day sacrificed 
No. rats with  No. rats 
clinical  signs  with lesions 
of AE~;  of AE 
0  0 
Proportion of rats with 
AE on day sacrificed 
o/18§ (0%) 
7 
8 
12 
14 
15 
16 
17 
18 
19 
20 
21 
27 
29 
39 
42 
44 
63 
1 
1 
3 
3 
10 
5 
3 
3 
2 
1 
2 
1 
1 
42 
24 
5 
9 
4 
5 
22 
17 
72 
20 
19 
13 
16 
32 
56 
26 
33 
0 
0 
1 
0 
2 
5 
12 
6 
30 
5 
9 
4 
1 
0 
311 
111 
111 
4 
2 
2 
6 
4 
5 
21 
17 
68 
16 
14 
8 
10 
2 
6 
4 
1 
4/42  (10%) 
2/24  (8%) 
2/5  (4o%) 
6/9  (67%) 
4/4  (100%) 
3/5  (100%) 
21/22  (95%) 
17/17  (100%) 
68/72  (95%) 
16/20  (80%) 
14/19  (74%) 
8/13  (62%) 
10/16  (62%) 
2/32  (6%) 
6/56  (11%) 
4/26  (15%) 
1/33  (3%) 
* All rats sensitized to standard  guinea pig spinal cord-adjuvant emulsion via  the intra 
cutaneous  route as described in Materials  and Methods. 
Except for 3 rats,  all animals in this table and Tables  II to V with clinical signs were 
subsequently  found to have lesions of AE. 
§ Numerator, No.  of rats with lesions of AE with or without associated  clinical neuro- 
logical signs;  denominator,  No.  of  rats  sensitized  and  sacrificed on  postsensitization  day 
indicated. 
[[ Of the 3 rats with clinical signs when sacrificed on 42nd day,  the atax/a observed in 2 
had persisted  since the  11th  and  12th day after sensitization  whereas  the ataxia noted in 
the 3rd rat made its initial appearance  on day sacrificed. The 1 rat with signs when sacri- 
ficed on the 44th day had been paralyzed  previously, had recovered and appeared  clinically 
well on the 17th day after sensitization  and remained well until o9th day when severe ataxia 
reappeared.  The ataxia in the 1 rat sacrificed on the 63rd day had persisted  since it initially 
appeared  on the 14th day after sensitization.  Routine sections of brain-spinal  cord from this 
rat as well as the 2 rats with persistence of clinical signs up to 42nd day had no microscopic 
lesions of AE. 
transitory disease. Almost all animals are afflicted by the 3rd week after sensi- 
tization,  most  show  full recovery by  the  5th  to  6th  week,  and  virtually no 
trace of disease exists by the 9th week. 
This pattern  of AE in  the  rat  was  an  important  clue which prompted  the 
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Suppression  of AE  in Rats  Treated  with Antibrain Serum.--A  serum-sup- 
pression experiment is shown in detail in Table IL Twelve rats were sensitized 
to spinal  cord plus  adjuvant; each received 2.0  ml of pooled antibrain rat 
serum on alternate days. All 12 animals remained clinically well through the 
19th day at which time they were sacrificed. In only 6 animals could AE lesions 
be found. Notable is the fact that 6 of the  12 serum-treated animals had no 
evidence of AE whatsoever. In contrast,  18  control rats sensitized with the 
same inocnlum but not treated with serum exhibited the expected incidence 
TABLE  II 
Suppression of Allergic Encephalomyelitis (AE) in Rats Sensitized to Nervous Tissue Plus Ad- 
ju~ant  and  Treated WiCk Antibrain  Rat  Serum  (Experiment R-8-60) 
Serum treatment* 
L0 ml pooled serum IV on day 
sensitized and alternate days 
thereafter through 18th post- 
sensitization day  ... 
.~'o serum.. 
No. of 
rats 
sensitized 
12 
18 
No. with clinical 
signs on days 
after sensitization 
1-7  8-14  15-19 !  Many  lesions 
0  0  0  2 
0  4  8  13 
No. with 
lesions~ 
Few 
lesions 
Proportion rats 
w~l~out evidence 
of AE~ 
6/12l[  (50%) 
1/18  (6%) 
* Serum pool used for treatment derived from sera collected from rats 6 weeks after sen- 
sitization to spinal cord plus adjuvant as described in MateriaLs  and Methods. 
All rats sacrificed on 19th day after sensitization -- 1 day after last injection of immune 
serum. Lesions of AE recorded as few or many in number as described in Materials and 
Methods. 
§ In this table and in Tables III to V, final results expressed in terms of rats failing to 
develop AE. 
[[ Numerator, No. of rats remaining clinically  well and having no demonstrable lesions 
of AE; denominator, No. of rats sensitized. 
and picture of AE. Four rats developed paralysis during the 2nd week. During 
the 3rd week, 1 of these 4 had recovered but 5 additional rats had developed 
neurological signs. Seventeen of the 18 rats were found to have characteristic 
AE lesions. In most of these  18  control animals the lesions were numerous, 
intense, and readily found in the brain and spinal cord. Only 1 of the 18 control 
rats failed to develop evidence of AE. 
Suppression of AE; Combined Results with Different Antibrain Serum Pools.-- 
The  results  of  several  experiments,  employing 8  different serum  pools  are 
presented in Table III. The results of treatment of small groups of rats with 
pooled  serum  derived  from either  previously paralyzed serum  donors  (e.g. 
pools 3-A, 4-A,  and f-A) or donors clinically well before bleeding (pools 3-B, 
4-B, or 5-B) gave comparable results and for convenience have been combined 762  SL~PRESSION  O~  ALLERGIC  ENCEPHA.LOM'YELITIS 
in tabulating the data in the upper part of Table III. The control groups (not 
serum-treated) for the serum-treated groups of rats are listed in the bottom of 
Table III in corresponding sequence. 
Of 48  animals sensitized and treated with serum,  only 3  developed clinical 
TABLE III 
Suppression  of AUergi~ EncephalomydiCis (AE)  in Sensiti~xl  Rats  Treated with Pooled 
Antlbrain Rat Serum 
Serum treatment*  .~ ~  No. with lesions 
•  of AE§ 
~  No. 
~ ~  with  Proportion rats 
i ~ ~  clinical  w/thout evidence  Do-  Vol-  Injection  Route  ~  i  of AE  ul~e  nors  Sen  r,~m  schedule  of  ~  o~  Many  Few 
bled  postsensiti-  injec-  o.  lesions  lesions 
tions  at:  ijected  zation 
wks.  ml  days 
6  2.0  Alternate 
3  2.0  Alternate 
3  1.0  Alternate 
6  2.0  Even 
1.0  Odd 
6  1.5  Alternate 
Serum 
ool 
o. 
8 
5-A, B 
3-A, B 
4-A, B 
VIII 
rotal... 
i.v.  12  0  2  4  6/12II 
i.v.  9  1  4  1  4/9 
i.v.  6  0  0  5  1/6 
i.v.  9  1  7  0  2/9 
i.Vo 
i.p.  12  1  2  7 
48  3/48  15/48  17/48 
~o serum (control groups of rats for those 
groups listed above) 
3/12 
16/48  (33%) 
18  9  13  4  1/18 
5  2  3  2  0/5 
5  2  5  0  0/5 
4  2  3  1  0/4 
12  8  9  3  0/12 
total...  44  23/44  33/44  10/44  1/44  (2%) 
* Serum pools prepared from sera of rats collected 3 or 6 weeks after sensitization to spinal 
cord-adjuvant and used for treatment as indicated. 
The 3 rats sensitized  and serum-treated exhibited initial neurological signs 10, 14, and 
16 days after sensitization, respectively. Clinical signs in control rats first noted  12  to 17 
days alter sensitization. 
§ Rats sacrificed on 19th postsensitization day except those animals treated with serum 
pools 3-A, B  (and corresponding control rats) which were sacrificed on 21st day. Lesions of 
AE recorded as few or many in number as described in Materials and Methods. 
][ Numerator, No. of rats failing to develop AE; denominator, No. of rats sensitized. 
signs of AE. The remaining 45 rats remained clinically well. Although 32 rats 
were found to have lesions, in the majority of these animals these lesions were 
few in number  and  tended  to be inconspicuous in character.  Sixteen  (33  per 
cent)  failed to develop either clinical or histological evidence of AE.  In con- 
trast,  similarly sensitized  control  rats  (given  no  serum)  regularly developed PHILIP  Y.  PATERSON  AND  S.  MARTIN  HARWIN  763 
AE. The majority of these animals had severe disseminated disease. Only 1 
of the 44 (2 per cent) failed to develop AE. 
Each  of  the  8  serum pools  exerted  a  consistent and  marked suppressive 
influence on development of AE. This fact is best appreciated by the rarity 
of clinical signs, the scanty nature of lesions, and more important, the rela- 
tively high proportion of rats without either clinical or histological evidence 
of AE in contrast to the situation in the control animals (bottom half of Table 
III, also see Table I). It may be seen, however, that the different serum pools 
varied in their capacity to suppress  AE.  This did not appear  to be  clearly 
related to time serum donors were bled, i.e. 3 or 6 weeks postsensitization, the 
volume of serum injected, or the route of injection. For example, using pool 8, 
disease  was  completely suppressed  in  half of  actively sensitized  recipients, 
each of which received 2.0 ml on alternate days. Using pools 4-A  and 4-B, 
also collected from donors at 6 weeks, less suppression of disease was noted in 
spite of the fact that each rat received one and a  half times as much serum. 
One additional experiment (not shown in Table III) should be mentioned. 
Two groups of 8 rats each were sensitized to spinal cord-adjuvant. One group 
was treated with antibraln serum  (collected from donors 3  to 6 weeks after 
sensitization) in the amount of 2.0 ml per rat just prior  to sensitization of 
serum recipients and again 48 hours after sensitization, respectively. Another 
group was not treated with serum. Both groups developed severe AE. At least 
6 animals in each group showed paralysis and virtually all had severe lesions. 
This lack of suppression in rats receiving only 2 injections of antibrain serum 
suggests that suppression of the disease shown in Table HI may require serum 
treatment for an appreciable period (even as long as 18 days) after exposure 
to nervous tissue-adjuvant emulsion. 
It seemed important to exclude the remote possibility that the occurrence 
of disease in the serum-treated rats was in part the resu/t of injecting antibrain 
serum. To this end, an antibrain serum pool, comparable in every respect to 
those previously used (Table III) was injected intravenously into a  group of 
8 norma~ rats. Each rat received 2.0 ml of serum on alternate days over an 
18  day observation period.  All remained  clinically well.  One  animal found 
dead on the 18th day and the remaining 7 rats sacrificed on the 19th day were 
found to have no demonstrable lesions of AE. The results of this experiment 
are in agreement with prior unsuccessful attempts  to transfer AE passively 
with immune serum carried out in this laboratory (28)  and by other workers 
(14).  This observation supports the view that suppression of AE by passively 
administered immune serum represents the equivalent of transfer of protection 
against the disease. 
Control  Serum  Pool Experiments.--Additional  experiments, in which simi- 
larly sensitized rats  were  treated  with  appropriate  control serum pools  are 
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time as  those  shown  in  Table  III  but  are presented  separately here  in  this 
fashion for convenience. Pools of serum prepared from rats sensitized to kidney 
plus  adjuvant  or  adjuvant  alone  or  pools  of  normal  rat  serum  exerted  no 
appreciable suppression of the disease. Over 50 per cent of the 57  sensitized 
rats  treated with  control serum developed clinical signs and  the majority of 
TABLE IV 
Lack of Suppression of Allergic Encephalomyditis  (A E) in Sensitized Rats Treated with Various 
Types of Control Rat Sera 
Type of serum treatment  (i.v. route) 
Status of serum donors 
Sensitized  to kidney 
plus adjuvant 
Sensitized  to  adju- 
vant only 
Sensitized  to  adju- 
vant only 
Normal rats 
Normal rats 
Normal rats 
Do-  Vol- 
nors  ume 
serum 
bled  in- 
at:  jected 
wks.  ml 
3  1.0 
3  2.O 
6  2.0 
,--  . 2.0 
--  2.0 
1.0 
--  • 2.0 
1.0 
Injection 
schedule 
postsensiti- 
zation 
No. of  with.  No. with  rats  Lesions 
sensitized  No.  of AE• 
to cord  Proportion  of 
and  cmncaL  rats  without 
adjuvant  lgn"  evidence 
and  SofS  of AE 
treated  AE*  Many  Few 
with 
serum 
days 
Alternate  5  4  4  t  0/5§ 
Alternate  7  3  4  3  0/7 
Alternate  15  6  11  1  3/15 
Alternate  9  7  7  0  2/9 
Even  10  5  6  4  9/10 
Odd 
Even  11  5  4  4  3/11 
Odd 
Total.  .]  57  30/57  36/57 13/57 8/57  (14%) 
* Initial appearance of clinical signs on llth to 17th postsensitization day. 
J: All rats sacrificed 19 days after sensitization (1 day after last injection of serum) except 
those  rats  treated  with  antikidney-adjuvant serum  which  were  sacrificed  21  days after 
sensitization. Lesions of AE recorded  as few or many in number as described in Materials 
and Methods. 
§ Numerator, No. of rats failing to develop AE; denominator, No. of rats sensitized. 
the animals were found to have many lesions. Only 8  of the 57 rats were free 
of AE. It should be noted that the time of collection of serum from the control 
donors,  the volume of serum pools injected into recipients, and  the schedules 
of serum  injection were  comparable  in  all respects  to  the  conditions  of  the 
antibrain  serum  pools which  gave  suppression  (Table III). The  data  (Table 
III and  IV)  strongly suggest that suppression of AE by antibrain serum ad- 
ministered passively is due  to  a  factor directed against nervous  tissue,  most 
likely antibrain antibody. The data in control  animals exclude  the  possibility PHILIP  Y.  PATERSON  AND  S.  MARTIN  HARWIN  765 
that the serum suppression of AE (Table III) is due to such non-specific factors 
as  ether  anesthesia,  handling  of  animals,  and  trauma  associated  with  the 
frequent injections; e.g., non-specific "stress." 
Is the Protective  Effect of Antibrain Serum Due to Complement-Fixing Anti- 
TABLE V 
Rdation, hlp between Complement-Fixlng (CF) Antibrain Antibody Content of Serum Pools 
and Effeaireness in Suppressing Allergic Emephalomyditis (AE)  in Rats 
Serum pool No.* 
5-B 
5-A 
4-B 
4-A 
3-B 
3-A 
VIII 
C'Hs0 fixed  by 
serum pool with 
brain antigen:[: 
61 
35 
39 
36 
25 
56 
34 
No. of rats 
sensitized 
and serum- 
treated 
4 
5 
6 
3 
3 
3 
12 
total  36 
Control pools  4, 4, 3, 1, 0  50 
VII  8  11 
6-2M  5  5 
rotal.  66 
No. with  No. with 
clinical 
signs  lesions 
of AE  of AE 
0  2 
1  3 
1  4 
0  3 
0  2 
0  3 
1  9 
3/36  26/36H 
27  42 
6  11 
2  4 
35/66  57/66H 
Proportion of rats 
~vithou~ evidence 
of AE 
2/4§ 
2/s 
2/6 
0/3 
1/3 
0/3 
3/12 
10/36 (28%) 
8/so 
o/11 
1/s 
9/66 (14%) 
* Serum pools, except VII and 6-2M, same as those recorded  in Tables II to IV. Pool 
VII derived from sera of rats collected  7 days after sensitization to spinal cord-adjuvant. 
Pool 6-2M prepared from sera collected from rats 1 to 6 weeks after spinal cord-adjuvant 
sensitization and found to fix 55 C~-Is0 before treatment with 2-mereaptoethanol (2M). 
No. of 50 per cent hemolytic units of complement  (C~Hs0), of exactly 100 C'Hs0 avail- 
able, fixed by 0.25 ml of serum in presence of rat brain antigen diluted usually 1 to 100 or 
1 to 250 in physiological saline. 
§ Numerator, No. of rats failing to develop AE; denominator, No. of rats sensitized. 
[] Of the 26 rats with lesions of AE, 13 had many lesions and 13 had few lesions; of the 
57 rats with lesions, 44 had many, severe, disseminated lesions and 13 had few lesions (see 
Materials and  Methods). 
body?--The  antibrain serum  pools were  prepared from  donors  3  or  6  weeks 
after sensitization, at  a  time known  from previous work  (25)  when  close to 
80 per cent of sensitized rats have detectable complement-fixing (CF) antibrain 
antibodies.  It  seemed  conceivable  that  the  suppressive  effect  the  antibrain 
serum pools exerted on the disease might be a  function of CF antibrain anti- 
body, known to be present in the pools. 
The relationship between the quantity of CF antibrain antibody in the serum 766  SUPPRESSION OF  ALLERGIC ENCEPHALOMYELITIS 
pools  (expressed  in  terms  of  C'Hs0  fixed  specifically with  brain  antigen  in 
vitro)  and  the suppressive effect the serum pools exerted on AE  is shown  in 
the upper portion of Table V. Similar data are set out in the bottom portion 
of Table  V  with  respect  to  5  control  serum  pools  (those  already shown  in 
Table IV)  and  1 antibrain serum pool prepared from sera collected from rats 
TABLE VI 
Levels of Passively Administered Complement-Fixing (CF) Antibrain  Antibody in Rats 
Sensitizzd to Nervous Tissue and Treated with Antibrain Serum Pools 
Pool No. 
3-A 
3-B 
5-A 
5-B 
Serum pool 
C'H~o fixed 
with brain 
antigen* 
56 
25 
35 
61 
Rat No. (sensitized 
and serum-treated) 
E  551 
E  553 
E  554 
E  555 
E  556 
E  557 
E  750 
E  751 
E  752 
E  753 
E  755 
E  746 
E  747 
E  748 
E  749 
Volume serum 
pool injected~ 
ml 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.O 
1.0 
C'I-15a  fixed  by 
rat serum on 
4th postsensiti- 
zation day 
17 
6 
4 
1 
10 
0 
9 
12 
5 
3 
0 
ll 
5 
12 
~Occurrence (+) 
or absence|O) 
o~ AE§ 
+ 
+ 
+ 
÷ 
0 
÷ 
0 
+ 
÷ 
÷ 
0 
+ 
0 
+ 
0 
* No. of 50 per cent hemolytic units of complement  (CIH50), of exactly 100 CtH~0 avail- 
able, specifically fixed by 0.25 ml of serum in presence of rat brain antigen. 
~t Serum injected just prior to sensitization of rats and on alternate days thereafter. 
§ Presence or absence of microscopic lesions of allergic encephalomyelitis (AE) in nervous 
tissue of rats on 19th or 21st postsensitization day. 
7  days after  sensitization. These  serum  pools in  agreement  with  prior work 
contained  little,  if  any,  CF  antibody.  In  addition,  data  are  also  presented 
concerning the suppressive activity of an antibrain serum pool collected from 
donors  1  to  6  weeks  after nervous  tissue sensitization and  shown  to  contain 
CF antibody. This pool (6-2M) before used was treated with 2-mercaptoethanol 
in order to  destroy the  CF antibody. In  earlier work  we  had  observed  (27) 
that the CF antibrain antibody produced by rats belongs to the high molecular PHILIP Y. PATERSON  AND  S. 3$ARTIN HARWIN  767 
weight (19S) class of gamma globulins  which are characteristically destroyed 
by treatment with 2-mercaptoethanol. 
The  data  (Table V)  indicate  dearly  that  all  serum pools containing  CF 
antibrain  antibody exerted a  suppressive effect on AE. Those pools lacking 
CF antibody had little, if any, suppressive influence on the disease.  The most 
telling experiment is that employing the 2-mercaptoethanol-treated  antibrain 
serum  pool.  This  pool before  2-mercaptoethanol  treatment  fixed  55  C'Hs0 
with rat brain antigen and  was comparable in this and  all other respects to 
the antibrain serum pools which did exert a suppressive effect (upper portion, 
Table V). This serum pool, following  treatment with 2-mercaptoethanol,  had 
neither  demonstrable  CF antibrain  antibodies  nor  suppressive  activity. 
It is clear  that no direct relationship  exists  between the  level of CF anti- 
brain antibody in a given serum pool and the suppressive activity of that pool 
(see  Table  V).  It  seemed  likely  that  one  explanation  for  this  observation 
might be variation in the level of CF antibrain  antibody passively achieved 
in individual recipient rats. Direct support for this interpretation is provided 
by the data presented in Table VI. 
Fifteen sensitized  and  serum-treated  rats  were bled from the retroorbital 
venus plexus on the 4th postsensitization day, just prior to the third injection 
of antibrain  serum. The individual serum samples were assayed for CF anti- 
brain  antibodies.  Since  it  is  known that  rats  actively sensitized  to  nervous 
tissue  plus  adjuvant  rarely  produce  CF  antibrain  antibody before the  5th 
to 7th postsensitization day (25),  any CF antibrain  antibody present in  the 
sera of these rats  on  the 4th  postsensitization  day represents passively ad- 
ministered  antibody.  Seven (Nos. 551,  556,  750, 751, 746, 747, and  749)  of 
the 15 recipient rats had small amounts of CF antibrain  antibody. The sera 
of these 7 rats fixed from 8 to 17 hemolytic units of complement (C'Hs0) spe- 
cifically with brain antigen.  The remaining  8 rats had little, if any, CF anti- 
brain antibody (less than 7 C'Hs0-fixed). It is of interest that of the 7 rats with 
CF antibrain  antibody on the 4th  postsensitization  day, 4  were completely 
protected from AE. In contrast, only 1 of the other 8 rats in which appreciable 
antibody was  not  demonstrable,  failed  to  develop evidence  of  the  disease. 
These observations suggest that a key factor in suppression of AE with anti- 
brain antibody is the level of CF antibody passively achieved. 
These findings  (Table VI) underscore the difficulty in achieving uniformly 
high  levels  of  CF antibrain  antibody administered  passively. The  levels  of 
CF antibrain  antibody achieved  passively in  sensitized  recipients  did vary 
when this point was checked (Table VI) and can be assumed to have varied 
in  other  recipients  receiving  serum  treatment.  This  fluctuation  in  antibody 
level seems adequate to account for the variability in degree of suppression of 
AE  observed from  one experiment  to  another,  irrespective of the  antibrain 
pool employed and its CF antibrain  antibody content at the time it was as- 
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DISCUSSION 
The clinical-pathological picture of AE in rats (Table I) has certain features 
which should be  emphasized. Albino rats  develop AE regularly following a 
single  injection  of  a  standard  spinal  cord  hornogenate-adjuvant  emulsion. 
Approximately half of the sensitized animals exhibit readily detected clinical 
neurological signs  by the  2nd  to 3rd  week after sensitization. At  this  time 
characteristic  microscopic  lesions  of  AE  can  be  demonstrated in  the  brain 
and/or spinal cord of almost all sensitized rats. From this point on, the majority 
of rats exhibit steady improvement and  tend to recover.  By the 4th to 6th 
week after sensitization most of the animals appear clinically well once again 
although recurrence of neurological signs  may be exhibited by an occasional 
rat  at this time. In similar fashion, lesions  of AE in this species  of animal, 
viz. focal vasculitis with associated perivascular demyelination, are found with 
progressively decreasing frequency during this same postsensifization period 
Around the 6th week a transitory resurgence of disease, lesions as well as signs, 
may occur. By the 9th week after sensitization virtually all rats are clinically 
well and microscopic lesions  of AE are virtually non-existent. The transitory 
nature of AE in the rat, with spontaneous and full recovery from the disease 
being the rule, stands in contrast to the more progressive or even fulminating 
and lethal course of the disease in certain other susceptible species of animals; 
e.g.,  the  guinea pig (8).  The fact that rats continue to produce CF antibrain 
antibody as they recover from acute manifestation of AE  (25)  led, in part, 
to  the thesis that CF antibrain antibody might have a  protective function. 
The data (Tables II and III) indicate that pooled serum collected from rats 
3 or 6 weeks after sensitization has the capacity to transfer passively protection 
against AE to actively sensitized rats. All antibrain serum pools tested to date 
have exerted a  suppressive effect which although clear cut is variable in in- 
tensity. This observation agrees with the preliminary finding of Florey (sum- 
marized by Vulp6,  reference 26),  that immune sera collected from guinea pigs 
sensitized to nervous tissue plus adjuvant may confer protection against AE 
on actively sensitized guinea pigs. The use of appropriate control serum pools 
(Table IV) in the present study supports the view that the suppressive effect 
obtained with antibrain rat serum is due to antibrain antibody. All antibrain 
serum pools found to contain appreciable levels of CF antibrain antibody (Table 
V) exerted a suppressive effect. Control serum pools and antibrain serum pools 
lacking CF antibrain antibody (Table  V)  gave no suppressive  effect. Note- 
worthy is the fact that a serum shown to have high titer CF antibrain antibody 
and treated with 2-mercaptoethanol, no longer has demonstrable CF activity 
and is devoid of any suppressive effect on AE. 
While the data strongly suggest that the factor in antibrain serum responsible 
for suppression of AE is CF antibrain antibody, it cannot be concluded that 
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antibrain antibody in a given serum pool and the suppressive effect that serum 
pool exerts.  One explanation for this lack of correlation  may be the difficulty 
in maintaining appreciable  levels of passively administered CF antibrain anti- 
body in recipient animals.  Data supporting this point and set out in detail 
above  (see text, discussion  of Table VI)  also  reveal  the importance of ap- 
preciable  levels of passively administered CF antibody for suppression of AE 
in individual recipient  rats. The in ~/vo absorption of passively administered 
antibody to the brain of actively sensitized recipients  or to spinal cord in the 
inoculum used for sensitization as well as a short half-life, e.g. 5 to 6 days, of 
passively administered gamma globulin  5 in the rat  (29) could  well account 
for variation in CF antibrain antibody levels achieved passively in individual 
recipients  and variation in degree of suppression of the disease. 
Previous studies (reviewed by Paterson, reference 8) have shown no direct 
relationship between occurrence  of CF antibrain antibody and occurrence  of 
AE in individual animals. The fact that CF antibody may be elicited by sen- 
sitization with certain non-mammalian nervous tissues  although these same 
nervous tissues do not cause AE indicates that CF antibody in all probability 
has no causal role in AE (13). These observations and the unsuccessful attempts 
by various workers to transfer AE to normal animals with antibraln serum (re- 
viewed  by Chase,  reference  14)  have been often cited  (15-17)  as  evidence 
that the CF antibraln antibodies represent an irrelevant immune response to 
nervous tissue  sensitization.  And, by implication,  that circulating antibrain 
antibody of any type has little to do with the pathogenesis  of AE. The ob- 
servations described  in this paper deal directly with this issue. Passively ad- 
mini.~tered antibrain serum consistently alters the expected  response  of rats 
to active sensitization to nervous  tissue;  v/z., AE is suppressed  or prevented. 
This observation has one inescapable meaning.  This meaning is that antibraln 
antibody does  not  represent  an  irrelevant  immune  response  and  must be 
given serious consideration  as a factor in AE. 
While the meaning of the observations  concerning serum suppression of AE 
described in this paper  is clear, the underlying mechanism(s)  is not. It may be 
useful to outline three current lines of thinking, knowing that each may re- 
quire modification in light of future work. These lines of thinking are presented 
in decreasing  order of probability, based on data in hand and experience of 
others set out in the immunologic literature. 
1.  -Passively Administered  CF Antibrain Antibody  Inhibits Active Production 
of the Immune Response Causing AE.--It has been shown that passively ad- 
ministered antibody may suppress  or inhibit active  production of antibody 
6 It may be important that the CF anfibrain antibody  produced by the rat is a heavy weight 
19S gamma globulin (27). Its half-life may be shorter than that for, presumably, 7S rat gamma 
globulin (29),  since half-life  of homologous  19S antibody in the guinea pig and the rabbit 
may be of the order of only 1 to 2 days (J. Uhr, and M. S. Finkelstein, unpublished observa- 
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by an  animal  against  the antigen in question.  Uhr and  Baumann  (30)  have 
reviewed key studies on this point and  presented  additional  data in guinea 
pigs and rabbits to document it. The recent study of Neiders et al.  (31) con- 
cerning  suppression of active production of anti-sheep  cell hemolysin in rats 
by repeated  injections  of  the  antibody  in  question  is  especially pertinent. 
It  was  shown  that  detectable  levels  of  circulating  hemolysin passively ad- 
ministered  are  necessary  for  inhibition  of  active  production  of  hemolysin. 
Our data strongly suggest that the suppressive influence of antibrain serum 
is a function of CF antibrain antibody, and that detectable levels of CF anti- 
brain  antibody passively administered  may be important  for suppression of 
AE (Table VI). CF antibrain antibody, although not causing AE itself, might 
suppress active production of another type of antibrain antibody. Such could 
occur if both antibodies are directed against basically dissimilar  brain antigens 
which,  however, share  at  least  one antigenic  grouping  or determinant.  For 
example,  CF  antibody  might  suppress  active  production  of  the  cytotoxic 
antibody shown by Bornstein and Appel (32) to be present in sera of rabbits 
and guinea pigs sensitized  to nervous tissue and developing AE. This cytotoxic 
antibody destroys myelin when added to tissue cultures of brain. In like manner, 
CF antibrain antibody may suppress delayed-type immune responses  against 
brain. Little evidence exists, however, which can be used to support the view 
that induction of delayed-type hypersensitivity in fact may be suppressed by 
passively administered antibody. 
2.  Passively Administered  Antibrain  Serum Inhibits  Production  of Antibody 
Responsible for AE.--The factor in antibrain serum responsible  for suppression 
of AE may not be CF antibody but another antibody, e.g. cytotoxic antibody, 
causing the disease. By providing this antibody passively, its active production 
may be suppressed. Viewed in this light,  the transfer of protection against AE, 
rather than transfer of the disease itself,  could be due to insufficient  levels of 
antibody, e.g. cytotoxic antibody, being achieved, the quality of the antibody 
transferred or difficulty of passively administered antibody crossing the blood- 
brain barrier  and reacting  with antigen  in the brain of the recipient.  If this 
line of thinking is correct, transfer of protection against AE represents evidence 
strongly suggesting  that  it is  serum antibody that  causes  AE.  It should be 
mentioned  that  other  work in  our  laboratory is  consistent with  this  thesis. 
For example,  AE is suppressed by whole body x-irradiation  and suppression 
of the disease is associated with marked  impairment  in circulating  antibrain 
antibody production  (20).  It  is  generally believed that  killed  mycobacteria 
are essential for rapid and regular induction of AE and that the importance of 
the  mycobacteria lies  in  their  capacity to  induce  immune  responses  of  the 
delayed-type against nervous tissue antigen.  This is not the case in the rat. 
AE may be induced in the rat equally well with or without killed mycobacteria PHILIP Y. PATERSON  AND  S. MARTIN  HARV/IN  771 
in the sensitizing  inoculum (24, 33). In rats, omitting mycobacteria does not 
impair  circulating  CF antibrain  antibody production  and  the  lymph  nodes 
draining  sites of sensitization  show  conspicuous production  of plasmacytes. 
3.  CF Antibrain Antibody May Act as "Blocking Antibody".--CF antibrain 
antibody  when  administered  passively might  combine  with  antigenic  sites 
in the sensitized recipient's nervous tissue without consequent tissue damage. 
In this fashion,  CF antibrain  antibody might  prevent  antigenic  sites  from 
binding  to  or  interacting  with  another  immune  factor  causing  AE,  be this 
circulating  antibody other  than  CF antibody,  "sensitized"  cells,  or some as 
yet not recognized  type of immune factor. 
In its operational aspects,  the suppression of AE in rats by passively ad- 
ministered antibrain serum is analogous to observations made by other workers 
in the field of tumor and transplantation immunology; viz., tumor enhancement 
and  prolongation  of skin  transplant  survivals.  This  analogy  can be readily 
appreciated  if  one  considers  autologous  mammalian  brain  to  represent  po- 
tentially foreign  tissue because it  contains  constituents  which  are  antigenic 
for the individual concerned.  In biological  terms, the occurrence of AE may 
be considered  to represent  an attempt  on the part of the animal  sensitized 
to nervous tissue (by injection of brain or spinal cord) to inadvertently reject 
its own (autologous) nervous tissue. Thus, the development of AE is equiva- 
lent to the rejection of a tumor transplant or a skin graft. It is well known that 
passively  administered  immune  serum,  collected  from  appropriate  donors, 
may interfere with or abolish the immune response required for rejection of 
tumor transplants  (34, 35).  Serum treatment may similarly interfere with the 
rejection of skin grafts  (36,  37).  It may be noteworthy that  the mechanism 
responsible for tumor  enhancement,  and  perhaps prolonged survival of skin 
grafts, by means of passively administered immune serum, most likely appears 
to be inhibition of active production of the immune factor in  question (35). 
Current studies are designed to answer,  if possible,  the general  question as 
to whether passively administered antibrain serum suppresses AE by inhibiting 
active responses  to antigenic stimulation or whether it exerts  its suppressive 
effect by acting on the target organ; i.e.,  the brain of the sensitized  animal. 
The use of the AE transfer model (18, 21, 22) may permit one to distinguish 
between these two modes of action. 
The work described in this paper is an outgrowth of continued studies of 
the relative role of serum factors, as well as cellular factors, in the pathogenesis 
of AE. It is hoped that  the suppression of AE by antibrain  serum described 
here may prove helpful in clarifying  the role of CF antibrain  antibody and 
other circulating antibrain antibodies in AE and help uncover clues that may 
lead to the eventual unraveling of the precise pathogenesis of AE. 772  SUPPRESSION OF ALLERGIC ~.NCEP~LOMYELITIS 
SUMMARY 
Rats  regularly develop evidence of allergic encephalomyelitis (AE)  2  to 3 
weeks following sensitization to nervous tissue plus adjuvant. Independent of 
the severity of AE which occurs, gradual recovery is the rule and by the 6th 
to  9th  week  after sensitization  rats  appear  clinically well  and  microscopic 
lesions of AE have virtually disappeared. 
Pooled serum collected from rats 3  or 6 weeks after sensitization contains 
complement-fixing  (CF)  antibrain  antibodies.  Such  pooled  serum  exerts  a 
striking suppressive influence on development of AE when passively admin- 
istered to rats  actively sensitized to nervous tissue.  Serum pools which  con- 
tain  CF  antibrain  antibody  suppress  the  disease.  Serum  pools  lacking  CF 
antibody do not suppress the disease. Serum containing CF antibrain antibody 
after treatment with 2-mercaptoethanol no longer fixes complement with brain 
antigen in vilro  and no longer suppresses AE in vivo.  The data suggest  that 
transfer  of  protection  against  AE  by passively  administered  antibrain  rat 
serum is due to an antibrain antibody, possibly the CF antibodies. The mean- 
ing of these findings is discussed in terms of the role(s) of circulating antibrain 
antibody in the pathogenesis of AE. 
The authors wish to express their thanks to Mrs. Dena Harwin who assisted in the serum 
treatment of rats throughout this study. Miss Elaine M. Cola and Miss Arlene M. Fox pro- 
vided valuable technical assistance during the latter part of the work. The encouragement 
and interest of Drs. Lewis  Thomas and H. S. Lawrence  were helpful to the authors throughout 
the entire study. 
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